Abstract
Evaluation of: Goss PE, Ingle JN, Pater JN et al.: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J. Clin. Oncol. 26(12), 1948–1955 (2008). Data from the National Institute of Canada MA.17 trial showed that patients who were disease free after 5 years of adjuvant treatment with tamoxifen had a 42% reduction of breast cancer recurrences (p < 0.001) when they received a further treatment with the nonsteroidal aromatase inhibitor letrozole, immediately or within 3 months from the end of tamoxifen.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Mrs E Byther assisted the author in the production of the English version of this manuscript.